Use of Biomarker Assessment of Nicotine Metabolism in Estimating the Risk of Cancer in People Who Smoke Tobacco

There are significant differences in the level of nicotine addiction, treatment, and the rate of relapse in different individuals, most of which attribute the effect of heredity.Accordingly, the use of biomarkers will allow the intensity of cigarette smoking as a relative indicator of the difference in the therapist s metabolism, in addition to predicting the situation of the person who consumes tobacco, will also be more influential on the decision to choose the appropriate treatment.Also, the risk of cancer is not the same among smokers. This is largely dependent on differences in the activity of cytochrome enzymes, especially cytochrome p450 Due to the involvement of this enzyme in the metabolism of nicotine in smokers and the clinical difference of individuals as a result of this difference, it seems that the use of clinical and biochemical criteria to differentiate individuals with slow and rapid metabolism (as a specific individual difference) is a way to evaluate The risk of developing cancer as a result of tobacco use and the differentiation of people at high and low risk of cancer for screening and paraclinical examinations is risk.Materials and Methods: In this study, the sample size with the power of 80 per cent and 5 per cent errors were calculated using the same study data and calculated according to the following formula. 122 patients were studied and the biomarker assessed the severity of smoking with the evaluation of monoxocarbon gas; serum creatinine and the number of cigarettes with the prevalence of cancer (lung, gastrointestinal, bladder), grade one relatives were evaluated. In the two groups of nicotine replacement therapy, the status of the response to treatment in individuals was metabolized and investigated rapidly.Results: There was a significant relationship between the rate of smoking biomarkers in people with fast and rapid metabolism and the prevalence of cancer in first-degree relatives, as well as nicotine replacement therapy through skin patches and those with fast metabolism and nicotine-binding > 0.001) was found.Discussion and Conclusion: The evaluation of smoking intensive biomarkers in differentiating smokers with metabolic processes is a quick and slow way to be considered, which seems to be supported by supplementary studies with a higher sample size in terms of screening severity in smokers. Be practical.